Browsing ODA Open Digital Archive by Author "Wist, Erik"
Now showing items 1-2 of 2
-
Fatigue During and After Breast Cancer Therapy—A Prospective Study
Reinertsen, Kristin Valborg; Engebråten, Olav; Loge, Jon Håvard; Småstuen, Milada Cvancarova; Naume, Bjørn; Wist, Erik; Edvardsen, Hege; Wille, Elisabeth; Bjøro, Trine; Kiserud, Cecilie E. (Journal article; Peer reviewed, 2017)Context Chronic fatigue (CF) in breast cancer (BC) survivors is multifactorial and may be caused by immune activation triggered by BC or its treatment. In the Neoadjuvant Avastin in Breast Cancer study, BC patients ... -
Time series analysis of neoadjuvant chemotherapy and bevacizumab-treated breast carcinomas reveals a systemic shift in genomic aberrations
Møller, Elen Kristine; Nord, Silje; Wedge, David C.; Lingjærde, Ole Christian; Silwal-Pandit, Laxmi; Gythfeldt, Hedda; Vollan, Hans Kristian Moen; Fleischer, Thomas; Krohn, Marit; Schlichting, Ellen; Borgen, Elin; Garred, Øystein; Holmen, Marit Muri; Wist, Erik; Naume, Bjørn; Van Loo, Peter; Børresen-Dale, Anne-Lise; Engebråten, Olav; Kristensen, Vessela N. (Genome medicine;10(1), Journal article; Peer reviewed, 2018-11-29)Background Chemotherapeutic agents such as anthracyclines and taxanes are commonly used in the neoadjuvant setting. Bevacizumab is an antibody which binds to vascular endothelial growth factor A (VEGFA) and inhibits its ...